WESTLAKE VILLAGE, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a direct purchase program to help those with diabetes obtain the company’s inhaled insulin, Afrezza, for as little as $4 a day. Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.
“It is important for MannKind to help those whose lives depend on insulin, and, unfortunately, over 65,000 uninsured or under-insured patients today must pay cash for their insulin each month, typically at the pharmacy counter at prices that reflect the costs of the pharmaceutical distribution chain,” said Michael Castagna, Chief Executive Officer of MannKind. “Our new Afrezza Patient Direct Program enables us to streamline the numerous costs and inefficiencies that exist in today’s healthcare system, so we can pass along the savings directly for these patients. We want to be part of the solution for the future of healthcare and healthy living.”
Participation in this innovative cash program, which is available to all eligible patients with a valid prescription, is simple. The first 1,000 people to register at www.insulinsavings.com will gain access to introductory pricing for the Afrezza Patient Direct Program, giving them the opportunity to purchase Afrezza for as little as $4 a day for the first twelve months. All participants who sign up for the program will gain access to attractive cash pricing for Afrezza.